Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probucol reduces plasma lipid peroxides in man.

J R Paterson1, A G Rumley, K G Oldroyd

  • 1Institute of Biochemistry, Royal Infirmary, Glasgow, UK.

Atherosclerosis
|November 1, 1992
PubMed
Summary

Probucol, a lipid-lowering drug, significantly reduces lipid peroxidation in hyperlipidaemic patients. This antioxidant effect, potentially via free radical scavenging, persists even after treatment cessation, suggesting a role in managing atherosclerosis progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans.

Atherosclerosis·2025
Same author

Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.

Journal of internal medicine·2019
Same author

Interaction of chylomicron remnants and VLDLs during ultracentrifuge separation based on the Svedberg flotation rate - Authors' response.

Journal of internal medicine·2019
Same author

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Journal of internal medicine·2019
Same author

Hepatitis C virus and atherosclerosis: A legacy after virologic cure?

Clinics and research in hepatology and gastroenterology·2016
Same author

Plasma lipid peroxide and serum vitamin E levels in subjects taking antipsychotic drugs.

Journal of psychopharmacology (Oxford, England)·2012

Area of Science:

  • Cardiovascular Pharmacology
  • Oxidative Stress Research

Background:

  • Probucol is a lipid-lowering agent with demonstrated antioxidant properties.
  • Animal studies suggest probucol may inhibit or delay atherosclerosis progression, possibly by preventing low-density lipoprotein oxidation.

Purpose of the Study:

  • To investigate the impact of probucol on free radical activity in hyperlipidaemic patients.
  • To assess the duration of probucol's antioxidant effects.

Main Methods:

  • Hyperlipidaemic patients received probucol treatment.
  • Plasma lipid peroxides were measured at baseline, 4 weeks, 12 weeks, and 4 weeks post-treatment.
  • Plasma vitamin E levels were also monitored.

Main Results:

Related Experiment Videos

  • Significant reduction in plasma lipid peroxide concentrations during probucol treatment compared to baseline.
  • Sustained reduction in lipid peroxides observed 4 weeks after discontinuing probucol.
  • No significant changes in plasma vitamin E concentrations were noted.

    • Conclusions:

    • Probucol effectively reduces lipid peroxidation in hyperlipidaemic patients.
    • The observed antioxidant effect may be attributed to a free radical scavenging mechanism.
    • These findings support probucol's potential therapeutic role in conditions associated with oxidative stress and atherosclerosis.